

# Hypothesis: Phytate is an important unrecognised nutrient and potential intravenous drug for preventing vascular calcification



Pieter Joubert<sup>a,b,\*</sup>, Markus Ketteler<sup>c</sup>, Carolina Salcedo<sup>a</sup>, Joan Perello<sup>a,d</sup>

<sup>a</sup> Laboratoris Sanifit, Parc Bit, Palma de Mallorca, Spain

<sup>b</sup> Institute of Pharmaceutical Science, King's College, London, UK

<sup>c</sup> Department of Nephrology, Klinikum Coburg, Coburg, Germany

<sup>d</sup> Institute of Health Sciences Research, University of Balearic Sciences, Palma de Mallorca, Spain

## ARTICLE INFO

### Article history:

Received 19 April 2016

Accepted 10 July 2016

### Keywords:

Vascular calcification

Phytate

Hydroxyapatite

Haemodialysis

End stage renal disease

Calciphylaxis

## ABSTRACT

Cardiovascular calcification (CVC) associated with conditions such as ageing, diabetes or renal impairment, results from the deposition of hydroxyapatite in the endothelium or media of blood vessels. Key medical management options are directed towards controlling plasma calcium and phosphate concentrations (e.g. parathormone inhibition, phosphate binders, dialysis), enhancing the effect of calcification inhibitors (e.g. fetuin-A, pyrophosphate, vitamin K, osteopontin, matrix Gla protein) and decreasing the effect of promoters of calcification (e.g. vitamin D, lipids, cytokines). Dietary phytate prevents the calcification of ageing in rats and epidemiological data suggest that phytate rich diets are associated with a lower incidence of CVC in the elderly. Intravenous phytate prevents aggressive CVC induced by vitamin D in rats. We propose that phytate should be added to the list of inhibitors of vascular calcification. We further suggest that adequate dietary phytate could prevent mild forms of calcification and that the low phytate content of diets for patients with renal disease can contribute to the increased risk of vascular calcification. It is also our contention that supra-physiological systemic phytate concentrations not achievable orally, might prevent aggressive vascular calcification. Appropriate epidemiological (to determine nutritional value) and clinical studies (evaluating safety and efficacy) are required to confirm, modify or reject our hypothesis.

© 2016 Elsevier Ltd. All rights reserved.

## Background

The influence of nutrition is widely recognised as crucial to understanding the pathophysiology, progression and prevention of disease. This perception is evident from the impact of epidemiological data, such as from the Framingham study, on modern medical practice and a plethora of publications on the impact of dietary fat, carbohydrates and other life style factors on cardiovascular risk factors [1].

The current concept of the pathophysiology of cardiovascular calcification (CVC) is that an excess of calcium and/or phosphate results in CVC due to the formation of hydroxyapatite (HAP) crystals in the vascular endothelium and media [2–4]. There are several

natural promoters of this process (e.g. vitamin D, lipids, inflammatory cytokines) and inhibitors (e.g. fetuin-A, pyrophosphate, vitamin K, osteopontin, matrix Gla protein). Current treatment options to prevent CVC are aimed at:

- reducing plasma calcium and phosphate (controlling the  $\text{Ca} \times \text{P}$  product) [5];
- enhancing the effects of inhibitors or reducing the effects of promoters of CVC.

Although the pathophysiology of cardiovascular calcification is complex, the final common pathway in the process is the formation, irrespective of the main cause, of HAP crystals.

A few available published nonclinical studies, as well as a limited number of small epidemiological studies, have stimulated our interest in the impact of phytate on CVC. In a study in rats which lasted 76 weeks, the ageing-associated development of CVC was enhanced by dietary phytate deficiency and prevented by a phytate-rich diet [6]. When aggressive CVC is induced by vita-

*Abbreviations:* CAC score, coronary artery calcium score; CKD, chronic kidney disease; CVC, cardiovascular calcification; ESRD, end stage renal disease; HD, haemodialysis; IP6, myo-inositol hexaphosphate; MBD, mineral bone disorder.

\* Corresponding author at: Laboratoris Sanifit, Parc Bit, Building Europa, 07121 Palma de Mallorca, Spain.

E-mail address: [pieter.joubert@sanifit.com](mailto:pieter.joubert@sanifit.com) (P. Joubert).

min D administration in rats, intravenous phytate administration (producing supra-physiological phytate concentrations), reduced aortic and heart calcification by 60 and 70% respectively [7]. Urinary phytate appears to be a good indicator of dietary phytate intake [8]. Fernández-Palomeque et al. [9] studied 188 patients (mean age 68 years) who were referred to a cardiology centre for cardiac echocardiography and who had evidence of cardiac valve calcification. Patients with the presence of valvular calcification, showed lower urinary phytate concentrations, compared to patients with no valvular calcification. These findings suggested that adequate dietary phytate might protect against the CVC of ageing in humans as well as in rats. There is further support for our contention in a non-clinical study reported by Moe et al. [10] They developed a model of inducing slowly developing chronic kidney disease-mineral bone disorder (CKD-MBD) over a period of 38 weeks with protein-fed Cy/+ rats (a genetic strain that develops renal impairment due to polycystic kidneys) receiving a normal phosphorus intake. These animals develop typical CVC, hyperparathyroidism and bone demineralisation. The severity of CKD and its associated features was most profound when the source of dietary protein was casein based. When the protein source was grain-based, the CKD including calcification, was significantly attenuated. The authors attributed this to the poor bioavailability of phosphorus (mainly in the form of phytate) in grain-based protein. It should be pointed out that this paper describes an animal model for inducing CKD with similar features to CKD-MBD in humans and was not aimed at studying the effects of phytate. We accept that they describe a very useful animal model for studying CKD. We however propose that an additional or alternative explanation for the reduced severity of CKD in animals fed grain compared to animals fed casein, could be that the grain-fed animals were protected by the phytate content, whereas the animals fed casein, were phytate-deficient.

The degree and rate of progression of CVC are accepted predictors of cardiovascular risk. The CAC (coronary artery calcium) score derived from computerized tomography scanning, is a widely accepted tool for assessing vascular calcification. The relationship between CAC scores and mortality has been described in many settings including the general population [11], the elderly [12], diabetics [13] and patients with chronic kidney disease without [14] or on haemodialysis (HD) [15]. As the baseline CAC score and the rate of progression of CAC scores are the key determinants of cardiovascular events including mortality, we believe that CAC score determination should be a key parameter in early human studies of the effect of phytate on CVC.

It is interesting to note that although there have been no large scale epidemiological studies on the effect of dietary phytate on health, there are several large studies showing an inverse relationship between cardiovascular mortality and the intake of nuts [16]. Nuts, in common with other plant seeds, are a dietary source of phytate.

### Presentation of the hypothesis

Phytate (myo-inositol hexaphosphate or IP6) is a polyphosphate and a normal dietary constituent found in seeds (e.g. whole grains, legumes, nuts and other seeds). Phytate is highly polar and therefore its absorption from the gastro-intestinal tract is limited. It prevents the formation of HAP crystals, the final common pathway in the pathophysiology of vascular calcification. In a paper on *in vitro* studies of the effects of polyphosphonates on hydroxyapatite crystals produced by solutions of calcium and phosphate ions, Francis [17] suggested that the chemisorption of polyphosphates on HAP might have a use in medical and dental conditions involving pathological calcium and phosphate metabolism.

Our hypothesis (Fig 1) is that dietary phytate deficiency is a key contributor to the CVC of ageing and that CVC can be attenuated by an adequate dietary intake of phytate. Furthermore we propose that patients with end stage renal disease (ESRD), particularly those on HD, have aggressive calcification due to a disturbed  $\text{Ca} \times \text{P}$  product (whatever the aetiology), superimposed on the background calcification due to ageing. As phosphates, including phytate, are intentionally restricted in the diet of ESRD, we suggest that dietary deficiency of phytate contributes to the occurrence and progression of CVC. Furthermore, due to its high water solubility and its consequent dialysability, phytate deficiency could be accentuated by dialysis. We suggest that supra-physiological phytate plasma concentrations, higher than achievable by the oral route, can be obtained by intravenous infusion and may prevent aggressive CVC as seen in patients with ESRD. It is also possible that phytate could have a role in the treatment of calciphylaxis [18], a rare disease occurring predominantly in HD patients and associated with debilitating painful skin ulcers, severe vascular and soft tissue calcification and a high mortality.

### Testing the hypothesis

Our contention that phytate has an important dietary role and has potential as an intravenous medication is an interesting hypothesis based on limited scientific information. There have been no large scale epidemiological studies on dietary phytate intake. Testing the hypothesis however is possible, but presents many challenges because large, long term studies will be required. Potential studies include:

- Prospective epidemiological studies of the relationship between dietary phytate and the calcification of ageing (retrospective and prospective) and cardiovascular events and mortality.
- Controlled studies of the effect of long term dietary phytate supplementation on vascular calcification and cardiovascular events and mortality in an ageing population. Before embarking on such studies, further research is needed to clearly define an upper limit of intake to avoid an impact on the absorption of essential nutrients.
- Studies with supra-therapeutic phytate concentrations obtainable by intravenous infusion vs. placebo in conditions associated with aggressive calcification (e.g. ESRD, diabetes, calciphylaxis). Long term studies are only practical in patients on HD where the intravascular route is regularly available during dialysis sessions. Studies will be difficult, requiring large numbers of patients, long study duration and assessment of CVC-related events, including mortality, as an endpoint.
- Calciphylaxis might be a target for a study with smaller patient numbers and shorter study duration. As the condition is rare and associated with a high CVC-related mortality and morbidity, study logistics and design will be a challenge. If it can be shown in this population that reducing vascular calcification reduces mortality, calcification reduction could potentially be validated as an endpoint acceptable to regulatory authorities.

### Implications of the hypothesis

- **Pathophysiology:** We suggest that current models of the pathophysiology of the development of CVC should be adapted to include phytate as a naturally occurring inhibitor of vascular calcification along with fetuin-A, pyrophosphate, vitamin K, osteopontin and matrix Gla protein.
- **Nutrition:** The medical community and the general population should be informed about the sources and the potential benefit of adequate dietary phytate. Furthermore dietary restriction of




Fig. 1. Illustrated outline of the phytate hypothesis showing the dietary and renal failure components of vascular calcification.

phytate in patients with renal impairment and phytate loss during dialysis, may contribute to the development of CVC and might require advice on phytate intake by modifying diets. Recommending commercially available phytate preparations requires caution as excessive oral intake can cause dietary deficiencies due to chelation of important nutrients such as vitamin D and iron in the gastro-intestinal tract. We could find no publications documenting malabsorption due to excessive phytate intake. It should also be noted that calcium phytate is designated as a GRAS (Generally Regarded As Safe) substance by the FDA.<sup>19</sup>

- *Phytate as a medicine*: The bioavailability of phytate by the oral route is poor and we propose that supra-physiological phytate concentrations, only achievable by parenteral administration, could beneficially influence mortality and morbidity in severe forms of CVC such as seen in ESRD. Life-long intravenous phytate administration during dialysis sessions is a plausible approach in patients on haemodialysis, because of the easy availability of intravascular access during sessions. An intravenous phytate formulation (SNF472) is currently in the early stages of development [7] for the prevention of vascular calcification in patients on haemodialysis due to end stage renal disease or calciphylaxis. It should be pointed out that intravenous phytate has no effect on gastro-intestinal absorption of vit D and iron. Furthermore serum iron and vit D exposure are carefully controlled in ESRD patients on HD.

It seems logical that the earlier a preventive therapy is started in a pathological process, the greater the chance of success. It is therefore our opinion that the development of alternative parenteral routes of administration might extend administration to risk populations without easy regular intravenous access.

## Conclusions

Our hypothesis suggests that adequate dietary intake of phytate could prevent mortality and morbidity in milder forms of CVC, particularly associated with ageing. We furthermore suggest that dietary restriction of phytate in patients with renal impairment and phytate loss during dialysis, may contribute to the development of CVC. We therefore propose that current models of the pathophysiology of the development of CVC should be adapted to include phytate as a naturally occurring inhibitor of vascular calcification along with fetuin-A, pyrophosphate, vitamin K, osteopontin and matrix Gla protein.

Supra-physiological phytate concentrations that can potentially influence mortality and morbidity in severe forms of CVC require parenteral administration. To prevent the progression of CVC, an intravenous phytate formulation (SNF472) is currently under development for administration during HD sessions. It is also our opinion that the development of alternative routes of parenteral administration might extend administration to risk populations not on HD and without easy regular intravenous access.

## Competing interests

SNF472 an intravenous phytate formulation, is in early stage clinical development by Laboratoris Sanifit for the prevention of vascular calcification in end stage renal failure patients, as well as in patients with calciphylaxis.

All the authors are full time or part-time employees or consultants at Sanifit and receive salaries, consultancy fees and/or stock options for their contributions.

## References

- [1] Long MT, Fox CS. The Framingham Heart Study – 67 years of discovery in metabolic disease. *Nat Rev Endocrinol* 2016;3:177–83.
- [2] Vascular GiacelliM. Calcification mechanisms. *J Am Soc Nephrol* 2004;15:2959–64.
- [3] Moe M, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. *J Am Soc Nephrol* 2008;19:213–6.
- [4] Demer LL, Tintut Y. Vascular calcification: pathophysiology of a multifaceted disease. *Circulation* 2008;117:2938–48.
- [5] Smeeta S, Eddington H, Kalra PA. Vascular calcification: mechanisms and management. *Br J Cardiol* 2008;15:316–21.
- [6] Grases F, Sanchis P, Perello J, et al. Phytate reduces age-related cardiovascular calcification. *Front Biosci* 2008 May;1(13):7115–22.
- [7] Perelló J, Salcedo C, Ketteler M, Tur F, Tur E, Isern B, et al. Intravenous SNF472 inhibits vitamin D induced cardiovascular calcification in rats. *J Am Soc Nephrol* 2014;25. Abstract Supplement 233A.
- [8] Prieto RM, Fiol M, Perello J, et al. Effects of Mediterranean diets with low and high proportions of phytate-rich foods on the urinary phytate excretion. *Eur J Nutr* 2010;49:321–6.
- [9] Fernández-Palomeque C, Grau A, Perello J, et al. Relationship between urinary level of phytate and valvular calcification in an elderly population. *PLoS One* 2015 [DOL: 10.1371/journal.pone.0136560].
- [10] Moe SM, Chen NX, Seifert MF, et al. A rat model of chronic kidney disease-bone mineral is order (CKD-MBD) and the effect of dietary protein source. *Kidney Int* 2009;75:176–84.
- [11] Buddoff MJ, Young R, Lopez VA, et al. Progression of coronary calcium and incident coronary heart disease events: the multi-ethnic study of atherosclerosis. *J Am Coll Cardiol* 2013;61:1231–9.
- [12] Vliegenhart R, Oudkerk M, Hofman A, et al. Coronary calcification improves risk prediction in the elderly. *Circulation* 2005;112:572–7.
- [13] Agarwal S, Cox AJ, Herrington DM, et al. Coronary calcium score predicts cardiovascular mortality in diabetes. *Diabetes Care* 2013;36:972–7.

- [14] Russo D, Corrao S, Battaglai Y, et al. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. *Kidney Int* 2011;80:112–8.
- [15] Shantouf RS, Budoff MJ, Ahmadi N, et al. Total an individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. *Am J Nephrol* 2010;31:419–25.
- [16] Grosso G, Yang J, Marventano S, et al. Nut consumption on all-cause, cardiovascular, and cancer mortality risk: a systematic review and meta-analysis of epidemiologic studies. *Am J Clin Nutr* 2015;101:4783–93.
- [17] Francis MD. The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. *Calcif Tissue Res* 1969;3:151–62.
- [18] Ketteler M, Biggar PH, Brandenburg VM, et al. Epidemiology, pathophysiology, and therapy of calciphylaxis. *Dtsch Arztebl* 2007;104. A3481–5.
- [19] <http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260876.htm>.